Динамика распространённости и чувствительности БЛРС–продуцирующих энтеробактерий к различным антимикробным препаратам в ОРИТ России | КМАХ

Динамика распространённости и чувствительности БЛРС–продуцирующих энтеробактерий к различным антимикробным препаратам в ОРИТ России

Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(4):323-336

​ Эйдельштейн М.В., Страчунский Л.С., исследовательская группа РОСНЕТ
бета-лактамазы расширенного спектра энтеробактерии нозокомиальные инфекции
Раздел
Антибиотикорезистентность
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(4):323-336

Аннотация

Изучена распространённость продукции β-лактамаз расширенного спектра (БЛРС) среди нозокомиальных штаммов энтеробактерий, выделенных в ОРИТ различных регионов России в 1997-1998 гг. и 2003 г. Выявлено стремительное нарастание частоты встречаемости БЛРС, в основном за счёт распространениея β-лактамаз CTX-M-типа. Результаты оценки чувствительности штаммов-продуцентов БЛРС к различным препаратам in vitro свидетельствуют о значительном снижении активности небеталактамных препаратов (амикацина и ципрофлоксацина) за указанный период. Препаратами выбора для терапии нозокомиальных инфекций, вызванных продуцентами БЛРС, остаются карбапенемы и цефоперазон/сульбактам.

  • 1. Finegold S.M. In vitro efficacy of beta-lactam/ beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999; 12(Suppl 1):S9-14.
  • 2. Kimura K., Arakawa Y., Ohsuka S., et al. Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob Agents Chemother 1996; 40:1988-94.
  • 3. McLaughlin J.C., Barry A.L., Fuchs P.C., et al. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 33:223-30.
  • 4. Nomura S., Hanaki H., A. Nagayama. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. J Chemother 1997; 9:89-94.
  • 5. Rice L.B., Carias L.L., Etter L., Shlaes D.M. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob Agents Chemother 1993; 37:1061-64.
  • 6. Burgess D.S., Hall R.G. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2004; 49:41-6.
  • 7. Kang C.I., Pai H., Kim S.H., et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother 2004; 54:1130-3.
  • 8. Thomson K.S., Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
  • 9. Queenan A.M., Foleno B., Gownley C., et al. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42:269-75.
  • 10. Edelstein M., Edelstein I., Semchenkova D., Stratchounski L. The effect of large inoculaon in vitro activities of penicillin-inhibitor combinations and cefoperazone-sulbactam against ESBL-producing Escherichia coli and Klebsiella pneumoniae strains. (Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases), Prague, 2004. Abstr. P1723
  • 11. Procop G.W., Tuohy M.J., Wilson D.A., et al. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Clin Pathol 2003; 120:265-7.
  • 12. Spanu T., Luzzaro F., Perilli M., et al. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46:196-202.
  • 13. Winokur P.L., Eidelstain M.V., Stetsiouk O., et al. Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases. Clin Microbiol Infect 2000; 6:103-8.
  • 14. Paterson D.L., Mulazimoglu L., Casellas J.M., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
  • 15. Yu W.L., Jones R.N., Hollis R.J., et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40:4666-9.
  • 16. Graffunder E.M., Preston K.E., Evans A.M., Venezia R.A. Risk factors associated with extended-spectrum {beta}-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005$ 56:139-45.
  • 17. Sirot D., Champs C.De, Chanal C., et al. Translocation of antibiotic resistance determinants including an extended-spectrum beta-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 1991; 35:1576-81.
  • 18. Araque M., Rivera I. Simultaneous presence of blaTEM and blaSHV genes on a large conjugative plasmid carried by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Med Sci 2004; 327:118-22.
  • 19. Mammeri H., Van De L.M., Poirel L., et al. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49:71-6.
  • 20. Wang M., Sahm D.F., Jacoby G.A., Hooper D.C. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48:1295-9.
  • 21. Jones R.N., Pfaller M.A.. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9:708-12.
  • 22. Bouchillon S.K., Johnson B.M., Hoban D.J., et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004; 24:119-24.
  • 23. Nijssen S., Florijn A., Bonten M.J. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24:585-91.
  • 24. Edelstein M., Pimkin M., Palagin I., et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003; 47:3724-32.
  • 25. Методические указания МУК 4.2.1890-04. 2004. Определение чувствительности микроорганизмов к антибактериальным препаратам.
  • 26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 27. Mabilat C., S. Goussard. 1993. PCR detection and identification of genes for extended-spectrum β-lactamases, p. 553-562. In: Persing D.H., Smith T.F., Tenover F.C., White T.J. (eds.), Diagnostic molecular microbiology. Principles and Applications. American Society for Microbiology, Washington, DC.
  • 28. Edelstein M., Pimkin M., Dmitrachenko T., et al. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2004; 48:2808-15.
  • 29. Ekimov A., Edelstein M., Belousov E. A single-tube PCR with MGB Eclipse probes for detection of SHV-type extended-spectrum beta-lactamases (ESBLs). Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, 2004; Abstr. P944.
  • 30. Edelstein M., Ekimov A., Stratchounski L. Prevalence of mutations conferring extended-spectrum activity on SHV beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from Russian nationwide survey. Proceedings 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004. Abstr. C2-1331.
  • 31. Livermore D.M. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-84.
  • 32. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
  • 33. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
  • 34. Paterson D.L., Ko W.C., Von Gottberg A., et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7.
  • 35. Szabo D., Mathe A., Filetoth Z., et al. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45:1287-91.
  • 36. Paterson D.L., Ko W.C., Von Gottberg A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
  • 37. Ambrose P.G., Bhavnani S.M., Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47:1643-6.
  • 38. Maglio D., Ong C., Banevicius M.A., et al. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48:1941-7.
  • 39. Ромашов О. М., Яковлев С.В., Сидоренко С.В., Березин А.Г. Эффективность цефепима при лечении нозокомиальных инфекций, вызванных энтеробактериями–продуцентами бета-лактамаз расширенного спектра. Инфекции и антимикробная терапия 2003; 5.
  • 40. Yakovlev S., Romashov O., Sidorenko S.V., Eryomina L. Impact of extended-spectrum beta-lactamases produced by Gram-negative bacteria on efficacy of cephalosporins and quinolones. Proceedings 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, 2005: Abstr. P437.
  • 41. Yu W.L., Pfaller M.A., Winokur P.L., Jones R.N. Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae. Taiwan. Emerg Infect Dis 2002; 8:522-4.
  • 42. Bonnet R., Sampaio J.L., Labia R., et al. A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother 2000; 44:1936-42.
  • 43. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48:1-14.
  • 44. Perilli M., Ettorre D., Segatore B., et al. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli. FEMS Microbiol Lett 2004; 241:229-32.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились